Factors associated with improved glycemic control following continuous subcutaneous insulin infusion therapy in patients with type 2 diabetes uncontrolled with bolus-basal insulin regimens: An analysis from the OpT2mise randomized trial

被引：8

作者：

Metzger, Muriel ^{[1
]}

Castaneda, Javier ^{[2
]}

Reznik, Yves ^{[3
]}

Giorgino, Francesco ^{[4
]}

Conget, Ignacio ^{[5
]}

Aronson, Ronnie ^{[6
]}

de Portu, Simona ^{[7
]}

Runzis, Sarah ^{[7
]}

Lee, Scott W. ^{[8
]}

Cohen, Ohad ^{[9
]}

机构：

[1] Clalit Hlth Serv, Diabet Clin, Jerusalem, Israel

[2] Medtron Bakken Res Ctr, Maastricht, Netherlands

[3] Univ Caen, Dept Endocrinol, Cote Nacre Reg Hosp Ctr, Caen, France

[4] Univ Bari Aldo Moro, Sect Internal Med Endocrinol Androl & Metab Dis, Dept Emergency & Organ Transplantat, Bari, Italy

[5] Univ Hosp Clin, Diabet Unit, Endocrinol & Nutr Dept, Barcelona, Spain

[6] LMC Diabet & Endocrinol, Toronto, ON, Canada

[7] Medtron Int Trading Sarl, Tolochenaz, Switzerland

[8] Medtron Diabet, Northridge, CA USA

[9] Chaim Sheba Med Ctr, Inst Endocrinol, IL-52621 Tel Hashomer, Israel

来源：

DIABETES OBESITY & METABOLISM | 2017年 / 19卷 / 10期

关键词：

blood glucose self-monitoring; glycated hemoglobin; insulin infusion systems; insulin therapy; multiple daily injections; type 2 diabetes mellitus; MULTIPLE DAILY INJECTIONS; PUMP THERAPY; EFFICACY;

D O I：

10.1111/dom.12960

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This analysis investigated factors associated with the decrease in HbA1c in patients receiving continuous subcutaneous insulin infusion (CSII) in the OpT2mise randomized trial. In this study, patients with type 2 diabetes and HbA1c >8% following multiple daily injections (MDI) optimization were randomized to receive CSII (n = 168) or MDI (n = 163) for 6months. Patient-related and treatment-related factors associated with decreased HbA1c in the CSII arm were identified by univariate and multivariate analyses. CSII produced a significantly greater reduction in HbA1c than MDI, and the treatment difference increased with baseline HbA1c. In the CSII arm, the only factors significantly associated with decreased HbA1c were higher baseline HbA1c (P < .001), geographical region (P < .001), higher educational level (P = .012), higher total cholesterol level (P = .002), lower variability of baseline glucose values on continuous glucose monitoring (P < .001) and the decrease in average fasting self-monitored blood glucose at 6months (P < .001). These findings suggest that CSII offers an option to improve glycemic control in a broad range of patients with type 2 diabetes in whom control cannot be achieved with MDI.

引用

页码：1490 / 1494

页数：5

共 16 条

[1] Sustained efficacy of insulin pump therapy compared with multiple daily injections in type 2 diabetes: 12-month data from the OpT2mise randomized trial [J].